CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03940664

Acronym

NEOVASC-CD160

Enrollment

Registered

2019-05-07

Start date

2008-01-31

Completion date

2017-07-31

Last updated

2019-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical Retinal

Brief summary

The aims of this study were * to analyze CD160 expression in both normal and pathological eyes from human adults * to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Detailed description

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Interventions

OTHERimmunohistochemistry on Formalin fixed and paraffin embedded blocks

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

: * Patients with retinal surgery * Patients who agree to participate to the study * Major patient

Exclusion criteria

: * Patient under law protection * Minor patient

Design outcomes

Primary

Measure	Time frame	Description
CD160 staining intensity score	Day0	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD160. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD160 immunolabelling.

Secondary

Measure	Time frame	Description
CD105 staining intensity score	Day0	Formalin fixed and paraffin embedded blocks were used for immunohistochemistry using CD105. The immunolabelling was evaluated independently by 2 observers (CBR, AH) blinded to clinical data. The staining intensity (0: absent, 1: faint, 2: moderate, 3: strong) was assessed for CD105 immunolabelling.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026